Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multicenter randomized single-blind phase III trial of tazarotene cream in moderate acne vulgaris
CTR20230701Phase 3Completed
- Sponsor
- Ziyond Pharmaceutical
- Start
- Aug 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tazarotene in acne vulgaris, sponsored by Ziyond Pharmaceutical. Started Aug 2023; status: completed.
02
Drugs
tazarotene
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on CTR20230701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230701.